ReviewMolecular medicine (Cambridge, Mass.)2026
O-GlcNAcylation: the metabolic-immune translator in tumor evolution and treatment.
Review in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
O-GlcNAcylation is a dynamic post-translational modification of serine/threonine residues in proteins that modulates cellular activities by influencing the function of protein substrates, including their cellular localization, stability, and protein-protein interactions. The hexosamine biosynthesis pathway (HBP) utilizes various metabolites to synthesize uridine diphosphate N-acetylglucosamine, which serves as the substrate for O-GlcNAcylation. Metabolic reprogramming of tumors modulates HBP flux, thereby influencing O-GlcNAcylation levels. O-GlcNAcylation plays a pivotal role in regulating immune signaling pathways and their targets. Consequently, O-GlcNAcylation may act as a central node linking metabolic reprogramming and immune evasion. In this review, we summarize the current progress in understanding the role of O-GlcNAcylation in immunometabolism and explore how O-GlcNAcylation serves as a metabolic-immune translator that regulates tumor progression and therapeutic responses. Furthermore, we discuss the potential of O-GlcNAcylation as a therapeutic target, providing a promising new approach for cancer treatment.
Indexed as
Identifiers
42477538What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.